News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website


Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary Results


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.kluweronline.com/issn/0167-594X

Posted on: 03/12/2003

Source: Journal of Neuro-Oncology 61 (3): 267-273, February 2003

Copyright © 2003 Kluwer Academic Publishers

All rights reserved

Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary Results

Ali Chahlavi

Department of Neurological Surgery, Brain Tumor Institute, Cleveland Clinic Cancer Center, Cleveland Clinic, Cleveland, OH, USA

Andrew Kanner

Department of Neurological Surgery, Brain Tumor Institute, Cleveland Clinic Cancer Center, Cleveland Clinic, Cleveland, OH, USA

David Peereboom

Department of Hematology/Oncology, Brain Tumor Institute, Cleveland Clinic Cancer Center, Cleveland Clinic, Cleveland, OH, USA

Susan M. Staugaitis

Department of Anatomic Pathology, Brain Tumor Institute, Cleveland Clinic Cancer Center, Cleveland Clinic, Cleveland, OH, USA

Paul Elson

Department of Biostatistics, Brain Tumor Institute, Cleveland Clinic Cancer Center, Cleveland Clinic, Cleveland, OH, USA

Gene Barnett

Department of Neurological Surgery, Brain Tumor Institute, Cleveland Clinic Cancer Center, Cleveland Clinic, Cleveland, OH, USA

Abstract

In this IRB-approved retrospective study, we analyzed the efficacy of temozolomide on World Health Organization Grade II and III oligodendrogliomas, as well as mixed oligoastrocytomas, to determine if a correlation exists between the tumors' 1p status and control of growth by this new oral agent. We assessed six patients with oligodendrogliomas with 1p intact (38%) and 10 patients with 1p loss (62%), who received temozolomide. Chromosome 1p status was significantly associated with response to treatment using temozolomide. While nine of 10 patients (90%) with 1p loss responded to temozolomide, only two of six patients (33%) with 1p intact benefited from this treatment (p = 0.04). Although the number of patients evaluated was small, there was no association between 1p status and gender, age, and tumor grade. Gender, age, and tumor grade were similarly not correlated with response to chemotherapy.

This report is the first to find that patients harboring oligodendrogliomas with 1p loss are more likely to be sensitive to treatment with temozolomide than those that retain this chromosomal element. Larger prospective trials are needed to confirm these findings; however, temozolomide should be considered in the management of these tumors.

Keywords

oligodendroglioma, allelic loss 1p, temozolomide, chemotherapy, molecular genetics

Article ID: 5110476



Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740